Gelteq Limited (NASDAQ:GELS – Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 12,658 shares, a decrease of 62.6% from the July 30th total of 33,877 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 36,025 shares, the days-to-cover ratio is presently 0.4 days.
Analyst Ratings Changes
Separately, Weiss Ratings lowered shares of Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, June 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
Read Our Latest Analysis on Gelteq
Gelteq Stock Down 2.6%
Gelteq (NASDAQ:GELS – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.12) earnings per share (EPS) for the quarter.
Institutional Trading of Gelteq
An institutional investor recently bought a new stake in Gelteq stock. Susquehanna International Group LLP acquired a new position in shares of Gelteq Limited (NASDAQ:GELS – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned approximately 0.44% of Gelteq at the end of the most recent reporting period.
About Gelteq
Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.
Further Reading
- Five stocks we like better than Gelteq
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Gelteq Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelteq and related companies with MarketBeat.com's FREE daily email newsletter.
